PITX2 DNA-methylation also identifies patients in the group of breast cancer patients who received in addition to anthracycline-based chemotherapy endocrine therapy (n = 96) who have a significant longer DFS and those patients who have a significantly shorter DFS (HR 2.285, p = 0.024) (Fig. 2c). The gene discussed is PITX2; the disease is breast carcinoma.